Latest Industry Insights

Native Mass Spectrometry (MS) can be used to examine proteins in their natural, folded forms. In this blog, Marshall Bern, Ph.D., the Vice President of Research and Co-Founder of Protein Metrics, discusses how advances in this technique are being paired with cutting-edge charge deconvolution algorithms to improve analysis of antibodies and plasma glycoproteins.

We spoke to Steve Conly, Vice President & General Manager, Microbiology for BD Diagnostics Systems, to learn more about the challenges facing clinical microbiology labs, and how informatics and automation solutions can help overcome these.

Proteomics is a powerful technology for analyzing low-abundance proteins for disease research. But it’s stalled by imprecise and often irreproducible data analysis. Here, David Chiang, Founder of Sage-N Research, explains how his company uses multidimensional separation to improve peptide identification in MS/MS.

In collaboration with UConn, Sensorion have identified the first potential biomarker for noise-induced hearing loss, findings which were recently presented at the 53rd American Neurotology Society Annual Spring Meeting.

Whilst Mass Spectrometry is undoubted in its status as a central part of the proteomics toolkit, there is still debate about the way that MS data should be acquired and analyzed. Here, we talk to Florian Marty, Director Global Product Support at Biognosys AG, about why he believes that data-independent acquisition is a superior acquisition technique.

Research into major diseases is a time-critical field. Automation can help make research faster and more reproducible. In this blog, we discuss the advantages and challenges of incorporating automation into pathology with Coleman Stavish, Proscia Inc's Chief Technology Officer.

We spoke to Barbara Fallowfield, Commercial Manager, Mologic, to learn how improvements in diagnostics could help clinicians to overcome current antimicrobial stewardship challenges and tackle antimicrobial resistance.

We spoke to Dr Albert Luderer, CEO of Integrated Diagnostics to learn about the challenges of diagnosing lung nodules as benign or malignant, and how the Xpresys Lung 2 liquid biopsy test can help improve this process.

Necessity is the mother of invention, and nowhere is this more clearly demonstrated than in the laboratory. We caught up with Alex Studer, VP of Marketing and Innovation at INTEGRA Biosciences, to discuss the company’s aim to transform the world of pipetting.

With justice and health in the balance, modern forensic toxicology drug testing labs are expected to detect and quantify a wide range of drugs and metabolites, from Fentanyl to novel psychoactive substances (NPS), at very low levels in biological matrices. The drug concentrations also need to be correlated with the impairment of the individual with absolute certainty, but labs face increasing pressures due to growing caseloads, sample backlogs, and budget restrictions.